Dr. David Agus on CBS’s “Morning Rounds”

So the role of prostate cancer screening got discussed on the CBS television program “Morning Rounds” on Saturday, by Dr. David Agus (a well-known urologic oncologist) and others. The context was the recent data on the “overuse” of the PSA test in men of 75+ years of age. … READ MORE …

From Amsterdam yesterday: European perspectives on the PSA screening issue

A report on the Medscape Oncology web site, published late yesterday, discusses two presentations given yesterday at the European Cancer Conference 2013, currently being held in Amsterdam. … READ MORE …

Appropriate use of the PSA test for assessing risk of prostate cancer

The following quotation is from the abstract of a recent review of the appropriate use of the PSA test in the assessment of risk for prostate cancer: … READ MORE …

Men’s opinions on PSA testing and the USPSTF guideline: does it apply to ME?

A study just published in the American Journal of Preventive Medicine suggests that “The new USPSTF recommendation against PSA testing in all men may be met with resistance” on the part of male consumers. … READ MORE …

New “six-point” statement about prostate cancer screening (redux)

Three weeks ago we mentioned a new six-point statement about PSA screening developed at a meeting in Melbourne, Australia. We would note that an updated set of information about this statement is now available on the BJU International web site. … READ MORE …

PSA testing, life and health insurance, and full disclosure

Many readers of this blog quite certainly have strong opinions about the position of the American Cancer Society (ACS) on use of the PSA test in assessment of risk for prostate cancer. However, one does have to give credit where credit is due on a related matter. … READ MORE …

Do the new data from the PCPT “change the game” when it comes to PSA screening?

So, with the new, 15-year survival data from the Prostate Cancer Prevention Trial (PCPT) published earlier this week (as discussed in a prior post), a key question for many is “Do these data significantly change the rationale for or against widespread screening for risk of prostate cancer?” … READ MORE …

New, six-point statement about PSA testing issued at PCWC

According to a report on the Bloomberg.com web site, attendees meeting at the Prostate Cancer World Congress (PCWC) in Melbourne, Australia have issued a new, six-point consensus statement about the use of the PSA test in the initial detection of prostate cancer. … READ MORE …

Decision aids, PSA-based screening, and male decision-making

According to a newly published study in JAMA Internal Medicine, web-based and print-based decision aids do help men to resolve their own internal conflicts about whether or not to get PSA tests for risk of prostate cancer … READ MORE …

New data from the Rotterdam section of the ERSPC: we need better tools

New follow-up data from the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial at a median of 12.8 years suggest that the overall, absolute, prostate cancer-specific mortality rate was 1.8 per 1,000 men randomized or 0.18 percent. … READ MORE …

Risk for prostate cancer once screening ended (from the Göteborg cohort)

Many readers will want to be aware of a new article entitled “Incidence of prostate cancer after termination of screening in a population-based randomised screening trial” that has just been published in European Urology. … READ MORE …

What has your doctor told you about PSA testing?

According to a recent article in the Annals of Family Medicine, about 64 percent of 3,400 men aged between 50 and 74 years of age who participated in a survey conducted in 2010 stated that they had never had a conversation with their doctor about the pros and cons of PSA testing. … READ MORE …

AUA issues new toolkit on prostate cancer screening

In a message sent out to its members this morning, the American Urological Association (AUA) has announced the availability of a new “toolkit” of materials designed to help doctors and patients in discussions about the pros and cons of testing individuals for their risk of prostate cancer. … READ MORE …

More on the screening, biopsy, treatment sequence

There is another iterestinng video discussion available on line on the Medscape web site … this one between Andrew Vickers, DPhil, of Memorial Sloan-Kettering Cancer Center, and Sigrid Carlsson, MD, PhD, of the University of Göteborg in Sweden.
… READ MORE …

Does 120-day mortality after prostate biopsy outweigh any possible benefit of screening?

Back in 2008, Gallina et al. demonstrated that the risk for mortality at 120 days after a prostate biopsy was of the order of 2 deaths per 1,000 prostate biopsies, and historically this is the only population-based study ever to assess this risk. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,120 other followers